腫瘍内癌治療市場の評価：癌タイプ・技術・エンドユーザー・地域別の機会および予測 (2017～2031年)

世界の腫瘍内癌治療の市場規模は、2023年の2,026億7,000万米ドルから、2024年から2031年の予測期間中は10.33%のCAGRで推移し、2031年には4,448億2,000万米ドルの規模に成長すると予測されています。

世界のさまざまな地域での癌の有病率の拡大、製薬業界の拡大、R&D活動の活発化が市場の成長を後押ししています。American Cancer Societyによると、米国では2023年に195万8,310人が新たに癌に罹患し、60万9,820人が死亡すると推定されています。

予後を改善するために患者の個々の要件に合わせ、遺伝子プロファイルに合わせてカスタマイズできる免疫療法薬の採用が増加していることが、市場に有利な成長機会をもたらしています。mRNA癌ワクチンの有効性を調査するためのR&D活動の活発化も市場成長をさらに後押ししています。2023年には、治療用ワクチンが手術による腫瘍摘出後の膵臓癌の再発リスクを低減するかどうかを調査する第2相臨床試験が開始されました。この試験には、Memorial Sloan Kettering Cancer Center (MSK) および世界の約80施設で260人の患者が登録される予定です。この試験では、mRNAのアプローチが現在の標準的な治療法よりも優れているかどうかについての洞察が得られると期待されています。

投資の増加による事業機会の到来

世界のさまざまな地域で癌の有病率が高まっているため、いくつかの政府は新規治療ソリューションのR&D活動への投資を増やしています。癌は、患者やその家族だけでなく、社会の生活にも大きな経済的影響を及ぼすため、患者の迅速な治療や検査を支援するさまざまな対策への投資は、経済的な側面が強いです。癌研究に投資することで、さまざまな種類の癌の早期発見を支援することを目指しています。

戦略的提携が市場拡大をサポート

戦略的提携や協力関係を通じて、さまざまなバイオテクノロジー企業や製薬企業が、それぞれのリソースや専門知識を結集し、開発プロセスを迅速に進めるためのアイデア、経験、知識を組み合わせることができます。2022年2月、BioNTech SEは、癌に対するTCRベースの免疫療法を推進するため、Medigene AGと世界な戦略的提携を締結しました。この共同研究には、複数の標的構造が含まれる見通しです。

当レポートでは、世界の腫瘍内癌治療の市場を調査し、市場の定義と概要、市場規模の推移・予測、各種区分・地域別の詳細分析、産業構造、市場成長への影響因子の分析、ケーススタディ、競合情勢、主要企業のプロファイルなどをまとめています。

目次

第1章 調査手法

第2章 プロジェクトの範囲と定義

第3章 エグゼクティブサマリー

第4章 世界の腫瘍内癌治療市場の展望

• 市場規模・予測
• 癌の種類別
  • 乳癌
  • 肺癌
  • 結腸直腸癌
  • 前立腺癌
  • 頭頸部癌
  • 黒色腫
  • その他
• 技術別
  • ワクチン
  • モノクローナル抗体
  • 細胞療法
  • 免疫システムモジュレーター
  • 養子細胞移植
  • チェックポイント阻害剤
  • サイトカイン
  • その他
• エンドユーザー別
  • 癌研究センター
  • 専門クリニック
  • 病院
• 地域別
  • 北米
  • 欧州
  • 南米
  • アジア太平洋
  • 中東・アフリカ
• 企業別の市場シェア

第5章 世界の腫瘍内癌治療市場の展望：地域別

• 北米
• 欧州
• 南米
• アジア太平洋
• 中東・アフリカ

第6章 市場マッピング

• 癌タイプ別
• 技術別
• エンドユーザー別
• 地域別

第7章 マクロ環境と産業構造

• 需給分析
• 輸出入分析
• バリューチェーン分析
• PESTEL分析
• ポーターのファイブフォース分析

第8章 市場力学

• 成長促進要因
• 成長阻害要因 (課題・抑制要因)

第9章 規制の枠組みとイノベーション

• 特許の情勢
• 規制当局の承認
• イノベーション/新興技術

第10章 主要企業の情勢

• 市場リーダー上位5社の競合マトリックス
• 市場リーダー上位5社の市場収益分析
• M&A・ジョイントベンチャー (該当する場合)
• SWOT分析（主要企業）
• 特許分析（該当する場合）

第11章 価格分析

第12章 ケーススタディ

第13章 主要企業の見通し

• Pfizer, Inc.
• F. Hoffmann-La Roche Ltd.
• Amgen Inc.
• Bayer AG
• Bristol-Myers Squibb, Inc.
• Novartis AG
• Sanofi SA
• AstraZeneca, Inc.
• GlaxoSmithKline Pharmaceuticals Ltd.
• BioNTech SE

第14章 戦略的提言

第15章 当社について・免責事項

List of Tables

• Table 1. Pricing Analysis of Products from Key Players
• Table 2. Competition Matrix of Top 5 Market Leaders
• Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
• Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

• Figure 1.Global Intratumoral Cancer Therapies Market, By Value, in USD Billion, 2017-2031F
• Figure 2.Global Intratumoral Cancer Therapies Market, By Volume, in Million Units, 2017-2031F
• Figure 3.Global Intratumoral Cancer Therapies Market Share (%), By Type of Cancer, 2017-2031F
• Figure 4.Global Intratumoral Cancer Therapies Market Share (%), By Technology, 2017-2031F
• Figure 5.Global Intratumoral Cancer Therapies Market Share (%), By End-user, 2017-2031F
• Figure 6.Global Intratumoral Cancer Therapies Market Share (%), By Region, 2017-2031F
• Figure 7.North America Intratumoral Cancer Therapies Market, By Value, in USD Billion, 2017-2031F
• Figure 8.North America Intratumoral Cancer Therapies Market, By Volume, in Million Units, 2017-2031F
• Figure 9.North America Intratumoral Cancer Therapies Market Share (%), By Type of Cancer, 2017-2031F
• Figure 10.North America Intratumoral Cancer Therapies Market Share (%), By Technology, 2017-2031F
• Figure 11.North America Intratumoral Cancer Therapies Market Share (%), By End-user, 2017-2031F
• Figure 12.North America Intratumoral Cancer Therapies Market Share (%), By Country, 2017-2031F
• Figure 13.United States Intratumoral Cancer Therapies Market, By Value, in USD Billion, 2017-2031F
• Figure 14.United States Intratumoral Cancer Therapies Market, By Volume, in Million Units, 2017-2031F
• Figure 15.United States Intratumoral Cancer Therapies Market Share (%), By Type of Cancer, 2017-2031F
• Figure 16.United States Intratumoral Cancer Therapies Market Share (%), By Technology, 2017-2031F
• Figure 17.United States Intratumoral Cancer Therapies Market Share (%), By End-user, 2017-2031F
• Figure 18.Canada Intratumoral Cancer Therapies Market, By Value, in USD Billion, 2017-2031F
• Figure 19.Canada Intratumoral Cancer Therapies Market, By Volume, in Million Units, 2017-2031F
• Figure 20.Canada Intratumoral Cancer Therapies Market Share (%), By Type of Cancer, 2017-2031F
• Figure 21.Canada Intratumoral Cancer Therapies Market Share (%), By Technology, 2017-2031F
• Figure 22.Canada Intratumoral Cancer Therapies Market Share (%), By End-user, 2017-2031F
• Figure 23.Mexico Intratumoral Cancer Therapies Market, By Value, in USD Billion, 2017-2031F
• Figure 24.Mexico Intratumoral Cancer Therapies Market, By Volume, in Million Units, 2017-2031F
• Figure 25.Mexico Intratumoral Cancer Therapies Market Share (%), By Type of Cancer, 2017-2031F
• Figure 26.Mexico Intratumoral Cancer Therapies Market Share (%), By Technology, 2017-2031F
• Figure 27.Mexico Intratumoral Cancer Therapies Market Share (%), By End-user, 2017-2031F
• Figure 28.Europe Intratumoral Cancer Therapies Market, By Value, in USD Billion, 2017-2031F
• Figure 29.Europe Intratumoral Cancer Therapies Market, By Volume, in Million Units, 2017-2031F
• Figure 30.Europe Intratumoral Cancer Therapies Market Share (%), By Type of Cancer, 2017-2031F
• Figure 31.Europe Intratumoral Cancer Therapies Market Share (%), By Technology, 2017-2031F
• Figure 32.Europe Intratumoral Cancer Therapies Market Share (%), By End-user, 2017-2031F
• Figure 33.Europe Intratumoral Cancer Therapies Market Share (%), By Country, 2017-2031F
• Figure 34.Germany Intratumoral Cancer Therapies Market, By Value, in USD Billion, 2017-2031F
• Figure 35.Germany Intratumoral Cancer Therapies Market, By Volume, in Million Units, 2017-2031F
• Figure 36.Germany Intratumoral Cancer Therapies Market Share (%), By Type of Cancer, 2017-2031F
• Figure 37.Germany Intratumoral Cancer Therapies Market Share (%), By Technology, 2017-2031F
• Figure 38.Germany Intratumoral Cancer Therapies Market Share (%), By End-user, 2017-2031F
• Figure 39.France Intratumoral Cancer Therapies Market, By Value, in USD Billion, 2017-2031F
• Figure 40.France Intratumoral Cancer Therapies Market, By Volume, in Million Units, 2017-2031F
• Figure 41.France Intratumoral Cancer Therapies Market Share (%), By Type of Cancer, 2017-2031F
• Figure 42.France Intratumoral Cancer Therapies Market Share (%), By Technology, 2017-2031F
• Figure 43.France Intratumoral Cancer Therapies Market Share (%), By End-user, 2017-2031F
• Figure 44.Italy Intratumoral Cancer Therapies Market, By Value, in USD Billion, 2017-2031F
• Figure 45.Italy Intratumoral Cancer Therapies Market, By Volume, in Million Units, 2017-2031F
• Figure 46.Italy Intratumoral Cancer Therapies Market Share (%), By Type of Cancer, 2017-2031F
• Figure 47.Italy Intratumoral Cancer Therapies Market Share (%), By Technology, 2017-2031F
• Figure 48.Italy Intratumoral Cancer Therapies Market Share (%), By End-user, 2017-2031F
• Figure 49.United Kingdom Intratumoral Cancer Therapies Market, By Value, in USD Billion, 2017-2031F
• Figure 50.United Kingdom Intratumoral Cancer Therapies Market, By Volume, in Million Units, 2017-2031F
• Figure 51.United Kingdom Intratumoral Cancer Therapies Market Share (%), By Type of Cancer, 2017-2031F
• Figure 52.United Kingdom Intratumoral Cancer Therapies Market Share (%), By Technology, 2017-2031F
• Figure 53.United Kingdom Intratumoral Cancer Therapies Market Share (%), By End-user, 2017-2031F
• Figure 54.Russia Intratumoral Cancer Therapies Market, By Value, in USD Billion, 2017-2031F
• Figure 55.Russia Intratumoral Cancer Therapies Market, By Volume, in Million Units, 2017-2031F
• Figure 56.Russia Intratumoral Cancer Therapies Market Share (%), By Type of Cancer, 2017-2031F
• Figure 57.Russia Intratumoral Cancer Therapies Market Share (%), By Technology, 2017-2031F
• Figure 58.Russia Intratumoral Cancer Therapies Market Share (%), By End-user, 2017-2031F
• Figure 59.Netherlands Intratumoral Cancer Therapies Market, By Value, in USD Billion, 2017-2031F
• Figure 60.Netherlands Intratumoral Cancer Therapies Market, By Volume, in Million Units, 2017-2031F
• Figure 61.Netherlands Intratumoral Cancer Therapies Market Share (%), By Type of Cancer, 2017-2031F
• Figure 62.Netherlands Intratumoral Cancer Therapies Market Share (%), By Technology, 2017-2031F
• Figure 63.Netherlands Intratumoral Cancer Therapies Market Share (%), By End-user, 2017-2031F
• Figure 64.Spain Intratumoral Cancer Therapies Market, By Value, in USD Billion, 2017-2031F
• Figure 65.Spain Intratumoral Cancer Therapies Market, By Volume, in Million Units, 2017-2031F
• Figure 66.Spain Intratumoral Cancer Therapies Market Share (%), By Type of Cancer, 2017-2031F
• Figure 67.Spain Intratumoral Cancer Therapies Market Share (%), By Technology, 2017-2031F
• Figure 68.Spain Intratumoral Cancer Therapies Market Share (%), By End-user, 2017-2031F
• Figure 69.Turkey Intratumoral Cancer Therapies Market, By Value, in USD Billion, 2017-2031F
• Figure 70.Turkey Intratumoral Cancer Therapies Market, By Volume, in Million Units, 2017-2031F
• Figure 71.Turkey Intratumoral Cancer Therapies Market Share (%), By Type of Cancer, 2017-2031F
• Figure 72.Turkey Intratumoral Cancer Therapies Market Share (%), By Technology, 2017-2031F
• Figure 73.Turkey Intratumoral Cancer Therapies Market Share (%), By End-user, 2017-2031F
• Figure 74.Poland Intratumoral Cancer Therapies Market, By Value, in USD Billion, 2017-2031F
• Figure 75.Poland Intratumoral Cancer Therapies Market, By Volume, in Million Units, 2017-2031F
• Figure 76.Poland Intratumoral Cancer Therapies Market Share (%), By Type of Cancer, 2017-2031F
• Figure 77.Poland Intratumoral Cancer Therapies Market Share (%), By Technology, 2017-2031F
• Figure 78.Poland Intratumoral Cancer Therapies Market Share (%), By End-user, 2017-2031F
• Figure 79.South America Intratumoral Cancer Therapies Market, By Value, in USD Billion, 2017-2031F
• Figure 80.South America Intratumoral Cancer Therapies Market, By Volume, in Million Units, 2017-2031F
• Figure 81.South America Intratumoral Cancer Therapies Market Share (%), By Type of Cancer, 2017-2031F
• Figure 82.South America Intratumoral Cancer Therapies Market Share (%), By Technology, 2017-2031F
• Figure 83.South America Intratumoral Cancer Therapies Market Share (%), By End-user, 2017-2031F
• Figure 84.South America Intratumoral Cancer Therapies Market Share (%), By Country, 2017-2031F
• Figure 85.Brazil Intratumoral Cancer Therapies Market, By Value, in USD Billion, 2017-2031F
• Figure 86.Brazil Intratumoral Cancer Therapies Market, By Volume, in Million Units, 2017-2031F
• Figure 87.Brazil Intratumoral Cancer Therapies Market Share (%), By Type of Cancer, 2017-2031F
• Figure 88.Brazil Intratumoral Cancer Therapies Market Share (%), By Technology, 2017-2031F
• Figure 89.Brazil Intratumoral Cancer Therapies Market Share (%), By End-user, 2017-2031F
• Figure 90.Argentina Intratumoral Cancer Therapies Market, By Value, in USD Billion, 2017-2031F
• Figure 91.Argentina Intratumoral Cancer Therapies Market, By Volume, in Million Units, 2017-2031F
• Figure 92.Argentina Intratumoral Cancer Therapies Market Share (%), By Type of Cancer, 2017-2031F
• Figure 93.Argentina Intratumoral Cancer Therapies Market Share (%), By Technology, 2017-2031F
• Figure 94.Argentina Intratumoral Cancer Therapies Market Share (%), By End-user, 2017-2031F
• Figure 95.Asia-Pacific Intratumoral Cancer Therapies Market, By Value, in USD Billion, 2017-2031F
• Figure 96.Asia-Pacific Intratumoral Cancer Therapies Market, By Volume, in Million Units, 2017-2031F
• Figure 97.Asia-Pacific Intratumoral Cancer Therapies Market Share (%), By Type of Cancer, 2017-2031F
• Figure 98.Asia-Pacific Intratumoral Cancer Therapies Market Share (%), By Technology, 2017-2031F
• Figure 99.Asia-Pacific Intratumoral Cancer Therapies Market Share (%), By End-user, 2017-2031F
• Figure 100.Asia-Pacific Intratumoral Cancer Therapies Market Share (%), By Country, 2017-2031F
• Figure 101.India Intratumoral Cancer Therapies Market, By Value, in USD Billion, 2017-2031F
• Figure 102.India Intratumoral Cancer Therapies Market, By Volume, in Million Units, 2017-2031F
• Figure 103.India Intratumoral Cancer Therapies Market Share (%), By Type of Cancer, 2017-2031F
• Figure 104.India Intratumoral Cancer Therapies Market Share (%), By Technology, 2017-2031F
• Figure 105.India Intratumoral Cancer Therapies Market Share (%), By End-user, 2017-2031F
• Figure 106.China Intratumoral Cancer Therapies Market, By Value, in USD Billion, 2017-2031F
• Figure 107.China Intratumoral Cancer Therapies Market, By Volume, in Million Units, 2017-2031F
• Figure 108.China Intratumoral Cancer Therapies Market Share (%), By Type of Cancer, 2017-2031F
• Figure 109.China Intratumoral Cancer Therapies Market Share (%), By Technology, 2017-2031F
• Figure 110.China Intratumoral Cancer Therapies Market Share (%), By End-user, 2017-2031F
• Figure 111.Japan Intratumoral Cancer Therapies Market, By Value, in USD Billion, 2017-2031F
• Figure 112.Japan Intratumoral Cancer Therapies Market, By Volume, in Million Units, 2017-2031F
• Figure 113.Japan Intratumoral Cancer Therapies Market Share (%), By Type of Cancer, 2017-2031F
• Figure 114.Japan Intratumoral Cancer Therapies Market Share (%), By Technology, 2017-2031F
• Figure 115.Japan Intratumoral Cancer Therapies Market Share (%), By End-user, 2017-2031F
• Figure 116.Australia Intratumoral Cancer Therapies Market, By Value, in USD Billion, 2017-2031F
• Figure 117.Australia Intratumoral Cancer Therapies Market, By Volume, in Million Units, 2017-2031F
• Figure 118.Australia Intratumoral Cancer Therapies Market Share (%), By Type of Cancer, 2017-2031F
• Figure 119.Australia Intratumoral Cancer Therapies Market Share (%), By Technology, 2017-2031F
• Figure 120.Australia Intratumoral Cancer Therapies Market Share (%), By End-user, 2017-2031F
• Figure 121.Vietnam Intratumoral Cancer Therapies Market, By Value, in USD Billion, 2017-2031F
• Figure 122.Vietnam Intratumoral Cancer Therapies Market, By Volume, in Million Units, 2017-2031F
• Figure 123.Vietnam Intratumoral Cancer Therapies Market Share (%), By Type of Cancer, 2017-2031F
• Figure 124.Vietnam Intratumoral Cancer Therapies Market Share (%), By Technology, 2017-2031F
• Figure 125.Vietnam Intratumoral Cancer Therapies Market Share (%), By End-user, 2017-2031F
• Figure 126.South Korea Intratumoral Cancer Therapies Market, By Value, in USD Billion, 2017-2031F
• Figure 127.South Korea Intratumoral Cancer Therapies Market, By Volume, in Million Units, 2017-2031F
• Figure 128.South Korea Intratumoral Cancer Therapies Market Share (%), By Type of Cancer, 2017-2031F
• Figure 129.South Korea Intratumoral Cancer Therapies Market Share (%), By Technology, 2017-2031F
• Figure 130.South Korea Intratumoral Cancer Therapies Market Share (%), By End-user, 2017-2031F
• Figure 131.Indonesia Intratumoral Cancer Therapies Market, By Value, in USD Billion, 2017-2031F
• Figure 132.Indonesia Intratumoral Cancer Therapies Market, By Volume, in Million Units, 2017-2031F
• Figure 133.Indonesia Intratumoral Cancer Therapies Market Share (%), By Type of Cancer, 2017-2031F
• Figure 134.Indonesia Intratumoral Cancer Therapies Market Share (%), By Technology, 2017-2031F
• Figure 135.Indonesia Intratumoral Cancer Therapies Market Share (%), By End-user, 2017-2031F
• Figure 136.Philippines Intratumoral Cancer Therapies Market, By Value, in USD Billion, 2017-2031F
• Figure 137.Philippines Intratumoral Cancer Therapies Market, By Volume, in Million Units, 2017-2031F
• Figure 138.Philippines Intratumoral Cancer Therapies Market Share (%), By Type of Cancer, 2017-2031F
• Figure 139.Philippines Intratumoral Cancer Therapies Market Share (%), By Technology, 2017-2031F
• Figure 140.Philippines Intratumoral Cancer Therapies Market Share (%), By End-user, 2017-2031F
• Figure 141.Middle East & Africa Intratumoral Cancer Therapies Market, By Value, in USD Billion, 2017-2031F
• Figure 142.Middle East & Africa Intratumoral Cancer Therapies Market, By Volume, in Million Units, 2017-2031F
• Figure 143.Middle East & Africa Intratumoral Cancer Therapies Market Share (%), By Type of Cancer, 2017-2031F
• Figure 144.Middle East & Africa Intratumoral Cancer Therapies Market Share (%), By Technology, 2017-2031F
• Figure 145.Middle East & Africa Intratumoral Cancer Therapies Market Share (%), By End-user, 2017-2031F
• Figure 146.Middle East & Africa Intratumoral Cancer Therapies Market Share (%), By Country, 2017-2031F
• Figure 147.Saudi Arabia Intratumoral Cancer Therapies Market, By Value, in USD Billion, 2017-2031F
• Figure 148.Saudi Arabia Intratumoral Cancer Therapies Market, By Volume, in Million Units, 2017-2031F
• Figure 149.Saudi Arabia Intratumoral Cancer Therapies Market Share (%), By Type of Cancer, 2017-2031F
• Figure 150.Saudi Arabia Intratumoral Cancer Therapies Market Share (%), By Technology, 2017-2031F
• Figure 151.Saudi Arabia Intratumoral Cancer Therapies Market Share (%), By End-user, 2017-2031F
• Figure 152.UAE Intratumoral Cancer Therapies Market, By Value, in USD Billion, 2017-2031F
• Figure 153.UAE Intratumoral Cancer Therapies Market, By Volume, in Million Units, 2017-2031F
• Figure 154.UAE Intratumoral Cancer Therapies Market Share (%), By Type of Cancer, 2017-2031F
• Figure 155.UAE Intratumoral Cancer Therapies Market Share (%), By Technology, 2017-2031F
• Figure 156.UAE Intratumoral Cancer Therapies Market Share (%), By End-user, 2017-2031F
• Figure 157.South Africa Intratumoral Cancer Therapies Market, By Value, in USD Billion, 2017-2031F
• Figure 158.South Africa Intratumoral Cancer Therapies Market, By Volume, in Million Units, 2017-2031F
• Figure 159.South Africa Intratumoral Cancer Therapies Market Share (%), By Type of Cancer, 2017-2031F
• Figure 160.South Africa Intratumoral Cancer Therapies Market Share (%), By Technology, 2017-2031F
• Figure 161.South Africa Intratumoral Cancer Therapies Market Share (%), By End-user, 2017-2031F
• Figure 162.By Type of Cancer Map-Market Size (USD Billion) & Growth Rate (%), 2023
• Figure 163.By Technology Map-Market Size (USD Billion) & Growth Rate (%), 2023
• Figure 164.By End-user Map-Market Size (USD Billion) & Growth Rate (%), 2023
• Figure 165.By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023

Global intratumoral cancer therapies market is projected to witness a CAGR of 10.33% during the forecast period 2024-2031, growing from USD 202.67 billion in 2023 to USD 444.82 billion in 2031F. The growing prevalence of cancer in various regions across the globe, expansion of the pharmaceutical industry, and rising research and development activities are bolstering the market growth. As per the American Cancer Society, 1,958,310 new cases and 609,820 deaths related to cancer were estimated to occur in the United States in 2023.

The growing adoption of immunotherapy drugs that can be tailored to the individual requirements of the patients and customized to their genetic profile for improving outcomes is providing lucrative growth opportunities to the market. Increasing research and development activities for investigating the efficacy of mRNA cancer vaccines is further supporting the market expansion. In 2023, a phase 2 clinical trial was opened to investigate whether therapeutic vaccines reduce the risk of return of pancreatic cancer after the removal of tumors by surgery. The study is expected to enroll 260 patients at Memorial Sloan Kettering Cancer Center (MSK) and approximately 80 sites across the globe. The trial will be open to individuals who recently received pancreatic cancer diagnosis and who have not yet had treatments including radiation therapy, immunotherapy, and chemotherapy or surgery. During phase 1 the vaccine was well tolerated by most patients, with phase 2 expected to offer clarity on the vaccine and various potential benefits. The trial is expected to offer insights into whether the mRNA approach performs better as compared to the current standards of the treatment.

Increasing Investments Anticipated to Offer Opportunities

Due to the growing prevalence of cancer in various regions across the globe, several governments are increasing investment in research and development activities for novel treatment solutions. Cancer has a significant economic impact on the lives of the patients and their families as well as the society, therefore there is a strong economic front for investing in various measures that will support the faster treatment and testing of patients. By investing in cancer research, they aim to support early detection of different types of cancers. For 2023, the American Institute for Cancer Research joined One Voice Against Cancer for requesting USD 49 billion in base funding for the National Institutes of Health.

Furthermore, various leading market players are investing in cancer research activities. According to Novartis India MD, the company invests 20% of its revenue towards research activities, including cancer research. With the help of dedicated research activities, the recognition and unraveling of cancer complexities will become much easier.

Strategic Collaborations Support Market Expansion

Through strategic partnerships and collaborations different biotechnology and pharmaceutical companies can pool their resources and expertise to combine their ideas, experience, and knowledge for fast-tracking the development process. In February 2022, BioNTech SE entered a global strategic partnership with Medigene AG to advance TCR-based immunotherapies against cancer. The research collaboration is expected to encompass several target structures. BioNTech SE is expected to hold exclusive worldwide commercialization rights and will be responsible for developing TCR therapies that result from the collaboration.

Amgen Inc., one of the leading American multinational biopharmaceutical companies committed to easing patient suffering by manufacturing, delivering, discovering, and developing innovative human therapeutics launched Amgen Partners of Choice. The network aims to bring together the company's clinical leaders and research and development experts from eight research centers around the globe. The network expects to create various collaboration channels to expedite the transformational programs that are focused on selected tumor types and disease areas.

North America Accounts for Significant Market Share

The strong presence of various leading market players, the increasing prevalence of cancer in the region, and rising investments in research and development activities are supporting the expansion of the market in the region. According to the Canadian Cancer Society, it was estimated that there would be 239,100 new cancer cases and 86,700 cancer-related deaths in Canada in 2023. Increasing public-private research collaborations are expected to offer the advancement of new therapies, supporting the market expansion in North America. For instance, the Partnership for Accelerating Cancer Therapies (PACT), a five-year public-private research collaboration, is expected to facilitate uniform and systemic clinical testing of biomarkers for advancing the understanding of resistance to immunotherapies and mechanisms of treatment response.

Meanwhile, Europe is expected to witness significant growth in the coming years. The growth can be attributed to the rising research and development activities by the regional market players. Sanofi is conducting an interventional study to determine maximum administered dose or maximum tolerated dose and tolerability and safety of SAR441000 when administered intratumorally. The study is estimated to conclude in February 2024.

Rising Incidences of Lung Cancer Support Market Growth

According to the World Health Organization (WHO) lung cancer is the leading cause of cancer related to deaths across the globe and smoking is the leading cause of lung cancer, resulting in approximately 85% of all cases. The growth of the smoking populace is one of the major factors bolstering the demand for lung cancer therapies. Current technologies provide two approaches for intratumoral therapy in lung cancer, namely percutaneous and bronchoscopic. Bronchoscopic approaches are more suitable for tumors that grow deeper in the lungs and are more likely to obstruct or crush larger airways whereas percutaneous approaches are used for treating peripheral lung tumors that are present near the chest wall. Various research activities are underway to evaluate the efficacy of bronchoscopic intratumoral injection. For instance, a team of researchers from Hiser Medical Center of Qingdao, Shandong, China is conducting a study to evaluate the adverse reactions and therapeutic effects of cisplatin and endostar in patients suffering from lung squamous cell carcinoma.

Checkpoint Inhibitors Account for Significant Market Share

Due to various benefits associated with checkpoint inhibitors, the segment is anticipated to account for a significant share of the market over the forecast period. Rising product approvals by different regulatory bodies including FDA is further supporting the segmental growth. In 2023, GlaxoSmithKline Pharmaceuticals Ltd. won the first PD-1 approval.

Jemperli was cleared as an add-on for patients undergoing chemotherapy with recurrent or primary advanced endometrial cancer. For being eligible for the therapy, the tumor of the patient must be microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR). In phase 3 RUBY trial, it was observed that the addition of Jemperli to chemotherapy reduced death or risk of progression by 72% among patients with mismatch repair deficient or microsatellite instability-high tumors, while showing a progression-free survival improvement of 24%.

Future Market Scenario (2024 - 2031F)

Intratumoral immunotherapy is expected to bolster the effectiveness of cancer immunotherapies across a broad spectrum of malignancies. Addressing the barriers to intratumoral delivery can aid in maximizing the effectiveness of these therapies. Abundant opportunities are available to support the integration of novel biomaterials for providing sustained release and improved delivery of immunotherapies within tumors.

With the help of continuous advancements towards the development of intratumoral drug-releasing interventional implants and devices that facilitate tumor approach, intratumoral nanoDDS administrations are expected to offer a suitable alternative to conventional systemic drug delivery.

Key Players Landscape and Outlook

Key participants in the intratumoral cancer therapies market are GlaxoSmithKline Pharmaceuticals Ltd., BioNTech SE, Pfizer, Inc., F. Hoffmann-La Roche Ltd., and Amgen Inc. Increasing investments towards research and development activities and strategic collaborations are supporting the market expansion.

In 2023, BioNTech SE announced a partnership with the United Kingdom government to provide personalized mRNA cancer immunotherapies to up to 10,000 patients by 2030. The multi-year collaboration is expected to focus on cancer immunotherapies and the expansion of BioNTech's footprint in the country. The company aims to roll out and design randomized clinical trials with the potential for registration for the personalized mRNA cancer immunotherapies provided by the company in the United Kingdom.

Table of Contents

1.Research Methodology

2.Project Scope & Definitions

3.Executive Summary

4.Global Intratumoral Cancer Therapies Market Outlook, 2017-2031F

• 4.1.Market Size & Forecast
  • 4.1.1.By Value
  • 4.1.2.By Volume
• 4.2.By Type of Cancer
  • 4.2.1.Breast Cancer
  • 4.2.2.Lung Cancer
  • 4.2.3.Colorectal Cancer
  • 4.2.4.Prostate Cancer
  • 4.2.5.Head and Neck Cancer
  • 4.2.6.Melanoma
  • 4.2.7.Others
• 4.3.By Technology
  • 4.3.1.Vaccines
  • 4.3.2.Monoclonal Antibodies
  • 4.3.3.Cell Therapies
  • 4.3.4.Immunes System Modulator
  • 4.3.5.Adoptive Cell Transfer
  • 4.3.6.Checkpoint Inhibitors
  • 4.3.7.Cytokines
  • 4.3.8.Others
• 4.4.By End-user
  • 4.4.1.Cancer Research Centers
  • 4.4.2.Specialty Clinics
  • 4.4.3.Hospitals
• 4.5.By Region
  • 4.5.1.North America
  • 4.5.2.South America
  • 4.5.3.Europe
  • 4.5.4.Asia-Pacific
  • 4.5.5.Middle East & Africa
• 4.6.By Company Market Share (%), 2023

5.Global Intratumoral Cancer Therapies Market Outlook, By Region, 2017-2031F

• 5.1.North America*
  • 5.1.1.Market Size & Forecast
    • 5.1.1.1.By Value
    • 5.1.1.2.By Volume
  • 5.1.2.By Type of Cancer
    • 5.1.2.1.Breast Cancer
    • 5.1.2.2.Lung Cancer
    • 5.1.2.3.Colorectal Cancer
    • 5.1.2.4.Prostate Cancer
    • 5.1.2.5.Head and Neck Cancer
    • 5.1.2.6.Melanoma
    • 5.1.2.7.Others
  • 5.1.3.By Technology
    • 5.1.3.1.Vaccines
    • 5.1.3.2.Monoclonal Antibodies
    • 5.1.3.3.Cell Therapies
    • 5.1.3.4.Immunes System Modulator
    • 5.1.3.5.Adoptive Cell Transfer
    • 5.1.3.6.Checkpoint Inhibitors
    • 5.1.3.7.Cytokines
    • 5.1.3.8.Others
  • 5.1.4.By End-user
    • 5.1.4.1.Cancer Research Centers
    • 5.1.4.2.Specialty Clinics
    • 5.1.4.3.Hospitals
  • 5.1.5.United States*
    • 5.1.5.1.Market Size & Forecast
    • 5.1.5.1.1.By Value
    • 5.1.5.1.2.By Volume
    • 5.1.5.2.By Type of Cancer
    • 5.1.5.2.1.Breast Cancer
    • 5.1.5.2.2.Lung Cancer
    • 5.1.5.2.3.Colorectal Cancer
    • 5.1.5.2.4.Prostate Cancer
    • 5.1.5.2.5.Head and Neck Cancer
    • 5.1.5.2.6.Melanoma
    • 5.1.5.2.7.Others
    • 5.1.5.3.By Technology
    • 5.1.5.3.1.Vaccines
    • 5.1.5.3.2.Monoclonal Antibodies
    • 5.1.5.3.3.Cell Therapies
    • 5.1.5.3.4.Immunes System Modulator
    • 5.1.5.3.5.Adoptive Cell Transfer
    • 5.1.5.3.6.Checkpoint Inhibitors
    • 5.1.5.3.7.Cytokines
    • 5.1.5.3.8.Others
    • 5.1.5.4.By End-user
    • 5.1.5.4.1.Cancer Research Centers
    • 5.1.5.4.2.Specialty Clinics
    • 5.1.5.4.3.Hospitals
  • 5.1.6.Canada
  • 5.1.7.Mexico

All segments will be provided for all regions and countries covered

• 5.2.Europe
  • 5.2.1.Germany
  • 5.2.2.France
  • 5.2.3.Italy
  • 5.2.4.United Kingdom
  • 5.2.5.Russia
  • 5.2.6.Netherlands
  • 5.2.7.Spain
  • 5.2.8.Turkey
  • 5.2.9.Poland
• 5.3.Asia-Pacific
  • 5.3.1.India
  • 5.3.2.China
  • 5.3.3.Japan
  • 5.3.4.Australia
  • 5.3.5.Vietnam
  • 5.3.6.South Korea
  • 5.3.7.Indonesia
  • 5.3.8.Philippines
• 5.4.South America
  • 5.4.1.Brazil
  • 5.4.2.Argentina
• 5.5.Middle East & Africa
  • 5.5.1.Saudi Arabia
  • 5.5.2.UAE
  • 5.5.3.South Africa

6.Market Mapping, 2023

• 6.1.By Type of Cancer
• 6.2.By Technology
• 6.3.By End-user
• 6.4.By Region

7.Macro Environment and Industry Structure

• 7.1.Supply Demand Analysis
• 7.2.Import Export Analysis
• 7.3.Value Chain Analysis
• 7.4.PESTEL Analysis
  • 7.4.1.Political Factors
  • 7.4.2.Economic System
  • 7.4.3.Social Implications
  • 7.4.4.Technological Advancements
  • 7.4.5.Environmental Impacts
  • 7.4.6.Legal Compliances and Regulatory Policies (Statutory Bodies Included)
• 7.5.Porter's Five Forces Analysis
  • 7.5.1.Supplier Power
  • 7.5.2.Buyer Power
  • 7.5.3.Substitution Threat
  • 7.5.4.Threat from New Entrant
  • 7.5.5.Competitive Rivalry

8.Market Dynamics

• 8.1.Growth Drivers
• 8.2.Growth Inhibitors (Challenges and Restraints)

9.Regulatory Framework and Innovation

• 9.1.Patent Landscape
• 9.2.Regulatory Approvals
• 9.3.Innovations/Emerging Technologies

10.Key Players Landscape

• 10.1.Competition Matrix of Top Five Market Leaders
• 10.2.Market Revenue Analysis of Top Five Market Leaders (in %, 2023)
• 10.3.Mergers and Acquisitions/Joint Ventures (If Applicable)
• 10.4.SWOT Analysis (For Five Market Players)
• 10.5.Patent Analysis (If Applicable)

11.Pricing Analysis

12.Case Studies

13.Key Players Outlook

• 13.1.Pfizer, Inc.
  • 13.1.1.Company Details
  • 13.1.2.Key Management Personnel
  • 13.1.3.Products & Services
  • 13.1.4.Financials (As reported)
  • 13.1.5.Key Market Focus & Geographical Presence
  • 13.1.6.Recent Developments
• 13.2.F. Hoffmann-La Roche Ltd.
• 13.3.Amgen Inc.
• 13.4.Bayer AG
• 13.5.Bristol-Myers Squibb, Inc.
• 13.6.Novartis AG
• 13.7.Sanofi SA
• 13.8.AstraZeneca, Inc.
• 13.9.GlaxoSmithKline Pharmaceuticals Ltd.
• 13.10.BioNTech SE

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work

14.Strategic Recommendations

15.About Us & Disclaimer